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Symptoms and Activity Limitation in
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Fatigue Syndrome?
Todd E. Davenport 1,2*, Mary Lehnen 1, Staci R. Stevens 2, J. Mark VanNess 2,3,
Jared Stevens 2 and Christopher R. Snell 2
1Department of Physical Therapy, Thomas J. Long School of Pharmacy and Health Sciences, University of the Pacific,
Stockton, CA, United States, 2Workwell Foundation, Ripon, CA, United States, 3Department of Health, Exercise, and Sport
Sciences, College of the Pacific, University of the Pacific, Stockton, CA, United States
Post-exertional malaise (PEM) is the hallmark clinical feature of myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS). PEM involves a constellation of
substantially disabling signs and symptoms that occur in response to physical, mental,
emotional, and spiritual over-exertion. Because PEM occurs in response to over-exertion,
physiological measurements obtained during standardized exertional paradigms hold
promise to contribute greatly to our understanding of the cardiovascular, pulmonary,
and metabolic states underlying PEM. In turn, information from standardized exertional
paradigms can inform patho-etiologic studies and analeptic management strategies in
people with ME/CFS. Several studies have been published that describe physiologic
responses to exercise in people with ME/CFS, using maximal cardiopulmonary testing
(CPET) as a standardized physiologic stressor. In both non-disabled people and people
with a wide range of health conditions, the relationship between exercise heart rate (HR)
and exercise workload during maximal CPET are repeatable and demonstrate a positive
linear relationship. However, smaller or reduced increases in heart rate during CPET are
consistently observed in ME/CFS. This blunted rise in heart rate is called chronotropic
intolerance (CI). CI reflects an inability to appropriately increase cardiac output because
of smaller than expected increases in heart rate. The purposes of this review are to (1)
define CI and discuss its applications to clinical populations; (2) summarize existing
data regarding heart rate responses to exercise obtained during maximal CPET in
people with ME/CFS that have been published in the peer-reviewed literature through
systematic review and meta-analysis; and (3) discuss how trends related to CI in
ME/CFS observed in the literature should influence future patho-etiological research
designs and clinical practice.
Keywords: myalgic encephalomyelitis (ME), exercise, exercise test, heart rate, chronotropic incompetence (CI),
chronic fatigue syndrome
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INTRODUCTION
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
is estimated to affect 0.8 to 2.5 million people in the United States
(1). Ninety percent of cases are thought to go undiagnosed (1),
suggesting that people with ME/CFS are substantially under-
counted, under-diagnosed, and under-treated. The hallmark
clinical feature of ME/CFS is post-exertional malaise (PEM),
which involves a constellation of substantially disabling signs and
symptoms that occur in response to physical, mental, emotional,
and spiritual over-exertion. A number of criteria for ME/CFS
exist for clinical and research purposes (1–5). Criteria including
PEM appear to have the best face validity to differentiate ME/CFS
from other fatiguing health conditions (1, 6, 7). The pervasive
nature of PEM inME/CFS has led some working groups to revise
diagnostic criteria for ME/CFS to highlight the multi-system
deficits associated with exertion intolerance (1–3).
The importance of PEM in ME/CFS emphasizes the value
of studies that document abnormalities in exercise response
to advance understanding of the patho-etiology, potential
biomarkers, and functional disability associated with ME/CFS.
Heart rate is one objective measurement, which can be reliably
obtained from wearable biometric technology. A large body of
literature already exists that documents heart rate responses to
exercise in ME/CFS and other fatiguing health conditions. The
increasing availability and affordability of wearable biometric
technology has led to the observation that wearables could be
used for activity tracking and prediction of PEM, using cardiac
function as an early proxy for future symptoms. Therefore, the
purposes of this perspective are to (1) review the mechanisms for
cardiac control during exercise; (2) review the literature related
to heart rate responses and exercise in ME/CFS; and (3) discuss
the potential implications for aberrant heart rate responses in
ME/CFS and its relationship to interpreting the results of exercise
testing paradigms and analeptic activity management.
THE RELATIONSHIP BETWEEN HEART
RATE AND WORKLOAD IS REPEATABLE
AND PREDICTABLE
Under normal conditions, the relationship between heart rate
and workload increases linearly. Reliability of a measure is a
precursor to validity. Exercise heart rates at maximal exertion and
ventilatory anaerobic threshold (VAT) are highly reproducible
in both non-disabled individuals and individuals with various
health conditions (8–19). In addition, the relationship between
workload and heart rate is normally very reproducible (20). That
is to say, the correlation is subject to very low error variance.
These observations suggest that deviations in the incremental
increase in heart rate in response to each unit increase in
workload might suggest pathology. In other words, variation in
measurements during cardiopulmonary exercise testing (CPET)
in people with ME/CFS may reflect true biological variance
that can be functionally relevant and provide important patho-
etiological clues about the nature of ME/CFS. In healthy people,
peak VO2 reflects a 4-fold increase over resting VO2 (21),
which is accomplished by a 2.2-time increase in heart rate, a
0.3-fold increase in stroke volume, and a 1.5-fold increase in
arteriovenous oxygen difference (21). The elevation of one’s heart
rate is the largest contributor to both VO2 and the ability to
maintain exercise at maximal level workloads (21). Further, an
increase in heart rate is a variable of great interest to clinicians
and researchers when observing abnormal responses to exertion
and predicting possible consequences due to those abnormal
responses. A normal and intact heart rate response pattern to
exertion is necessary because cardiac output (heart rate × stroke




Chronotropic intolerance (CI) is defined by a range of different
criteria, including; failure to achieve age-predicted maximal
heart rate, delays in achieving age-predicted maximal heart rate,
inadequate heart rates at submaximal workloads, slowed post-
exertion recovery heart rate, or heart rate fluctuations (21, 22).
The prevalence of CI is poorly understood because it is non-
uniformly defined. Gentlesk et al. (22) reported the prevalence
of CI ranges from 3.1 to 11% in patients referred for exercise
testing, >40% in a population of patients with pacemakers, and
up to 60% in patients with atrial fibrillation (22). This variation
in prevalence provides further evidence in support of the need
for a clear definition and a standardized set of criteria so that
diagnosis of CI may be made appropriately and populations can
be compared (21).
CI is most often diagnosed using a percentage as the
cutoff for distinguishing between normal and abnormal heart
rate responses to incremental increases in workload during
an exercise test (23). The most common percentages of age-
predicted maximal heart rate that have been used range between
70 and 85% (23). CI also can be represented as a measure of
heart rate reserve, which is the change in heart rate from rest to
peak exercise measured during an exercise test (23). However,
since the heart rate reserve equation is dependent upon the
resting heart rate, it can be taken one step further to better
represent an individual’s heart rate response to exercise (23).
In other words, chronotropic response can be calculated as a




(23). Failure to obtain ≥80% of the adjusted
heart rate reserve during an incremental exercise test is the most
common criterion used to distinguish CI (23). Some researchers
prefer to take a more definitive route when measuring exertion.
The ratio of the volume of carbon dioxide produced to the
volume of oxygen consumed, or the respiratory exchange ratio,
represents an objective measure of physiologic effort during
exertion (23). It is generally accepted that a respiratory exchange
ratio of >1.15 is indicative of intense, maximal exercise, while a
ratio of <0.82 is indicative of a resting state. If an individual’s
respiratory exchange ratio is <1.05 at peak exercise, research
suggests that this indicates either a submaximal level of effort or a
premature termination of the exercise test and should be analyzed
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with caution (23). Similarly, in 1992, Wilkoff et al. (24) attempted
to diagnose CI in a more objective manner through the use
of the metabolic-chronotropic relationship, or the chronotropic
index, which is the ratio between heart rate reserve andmetabolic
reserve during submaximal workloads. Wilkoff et al. (24) chose
this method because it adjusts for age, physical fitness level,
functional capacity, and it is unaffected by a researcher’s choice
of exercise test or protocol. Under normal conditions in healthy
individuals, the percentage of heart rate reserve should match
the percentage of metabolic reserve achieved during exertion to
equal a chronotropic index of 1.0 with 95% confidence intervals
of 0.8 and 1.3 (24). Therefore, if the metabolic-chronotropic
relationship, or chronotropic index, is ≤0.8 from a given slope
or single value throughout one stage of an incremental exercise
test, then that is considered CI (24). The Wilkoff model for CI is




on age, resting heart rate, age-predicted maximal heart rate,
age-predicted heart rate reserve, maximal heart rate observed
during exercise testing, volume of oxygen consumed (VO2–
expressed as MET values; 3.5 ml/kg/min) at each stage and at
peak exertion, and respiratory exchange ratio (24). Further, this
equation can be combined with the previously discussedmethods
of age-predicted maximal heart rate, adjusted heart rate reserve,
and respiratory exchange ratio to determine whether or not CI
is present. For example, chronotropic index can be used as a
deciding factor if a subject achieves an adequate peak respiratory
exchange ratio of >1.09, but fails to achieve ≥80 or 85% of
adjusted heart rate reserve or age-predicted maximal heart rate,
or if a subject achieves a peak respiratory exchange ratio of
<1.09 (21). One can see that there are a number of methods for
distinguishing between a normal chronotropic response and CI,
which is dependent upon a handful of variables. It is imperative
that researchers work together to create a definition and criteria




Lauer et al. (25) examined prognostic implications of CI in
1,575 asymptomatic male participants from the Framingham
Offspring Study. In order to be designated asymptomatic,
participants were required to take part in an exercise treadmill
test (25). Researchers followed the participants for an average
of 7.7 years to investigate all-cause mortality and coronary
heart disease events, including angina pectoris, coronary
insufficiency, myocardial infarction, any type of coronary
heart disease deaths, and coronary revascularization (25).
The treadmill exercise test was terminated when participants
achieved 85% of age- and sex-predicted maximal heart rate
(25). Lauer et al. (25) also mentioned that treadmill tests were
terminated upon “participant request, limiting chest discomfort,
dyspnea, fatigue, leg discomfort, hypotension, an excessive
increase in systolic blood pressure (i.e., peak systolic pressure
≥250 mmHg), ≥2mm ST-segment depression, or significant
ventricular ectopy. Researchers distinguished between normal
and abnormal chronotropic responses using three different
variables—the ability or inability to achieve 85% of his age-
and sex-predicted maximal heart rate, an increase in heart rate
from rest to peak, and the chronotropic index at stage 2 of the
Bruce protocol (25). One thousand two hundred and forty-eight
participants (79%) achieved 85% of their age-predicted maximal
heart rates, while the remaining 327 participants (21%) failed to
achieve 85% of the target heart rate (25). The participants that
failed to reach the target heart rate were also at an increased
risk for an ischemic ST-segment response to appear on an
ECG, had a lower exercise capacity, and were related to higher
occurrences of all-cause mortality and coronary heart disease
events (25). The researchers found that increases in heart rate
with exertion were inversely related to mortality risk and that




PRESENT IN PEOPLE WITH ME/CFS
Our group (26, 27) and others (28–30) have measured
heart rate responses to exercise in ME/CFS using CPET
methodology that allows for careful characterization at peak
exertion and VAT. The specific protocol our group has used
for over 20 years was developed to capture the difference
in underlying physiology between the average symptomatic
state and potential cardiovascular, pulmonary, and metabolic
decrements characteristic of PEM (26, 28, 31–33). To begin,
patients are instructed to rest as much as possible before
performing the first CPET, which measures a baseline of
the individual and provides a physical stressor to induce
PEM. A second CPET performed 24 h after the first is then
conducted to measure the individual’s response to exercise
while in a post exertional state. Sedentary but otherwise
non-disabled individuals exhibit high levels of reproducibility
between tests (19, 34). Even individuals with various health
conditions that present with fatigue demonstrate reproducible
CPET measurements (9, 10, 13–17). However, the physiological
correlates of PEM, which are typically exacerbated by exertion,
are often indicated by variation outside expected intervals in
successive exercise tests. Therefore, changes on the test are not
related to poor reliability (i.e., “error variance”), but rather the
biological variance associated with ME/CFS.
We conducted a systematic review to locate primary research
articles published in the peer reviewed and so-called unpublished
“gray literature” that described chronotropic responses to
exercise during maximal cardiopulmonary exercise testing in
people with ME/CFS, with or without comparison to matched
control subjects. Maximal cardiopulmonary exercise testing was
chosen because there are uniform criteria described for test
cessation, and documented criteria exist to identify physiological
performance at the ventilatory anaerobic threshold (VAT), which
is the point at which non-oxidative or anaerobic metabolism
begins to significantly contribute to energy metabolism with
increasing exercise workloads (35, 36). Articles that reported
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FIGURE 1 | Flow diagram describing the systematic review.
mean age of participants and heart rate at either peak
exertion or VAT were included in the quantitative analysis.
We searched Medline Complete, CINAHL, Academic Search
Complete, SPORTDISCUS, and PsycINFO on 5 December 2018
using keywords [(SU exercise tests) OR (exercise physiology) OR
(cardiopulmonary system)] AND [(SU myalgic encephalomyelitis)
OR (SU chronic fatigue syndrome)]. We also conducted hand
searches of reference sections and included other known papers
that were not included in the search results. The systematic
review revealed 36 articles that were included in the quantitative
analysis (Figure 1).
CPET responses on a single test were assessed in the context of
a single maximal CPET in patients withME/CFS only (14 studies,
including 1,169 patients with ME/CFS) compared with otherwise
non-disabled individuals who were matched for gender and age
(17 studies, including 961 patients with ME/CFS and 529 control
subjects; Tables 1–3). Among these studies, 25 studies (28–30,
37–42, 47, 48, 52–60, 62, 63, 65–69) used the Fukuda et al. criteria
(4), four studies (43–45, 51) used the Oxford criteria (5), five
studies used the Holmes criteria (49, 50, 61, 64, 70), and one study
(46) used the Fukuda et al. criteria, Canadian Consensus Criteria
(2), and International Consensus Criteria (3). An additional four
studies (30, 66) comparedmeasurements obtained during a single
CPET between men and women with ME/CFS (Table 3); three
studies used the Fukuda criteria to identify ME/CFS (4). Three
other studies (28, 46, 65) compared the responses of individuals
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TABLE 1 | Heart rate measurements obtained at peak exertion during a single maximal cardiopulmonary exercise test in studies comparing subjects with myalgic
encephalomyelitis/chronic fatigue syndrome (n = 2,270) to matched control subjects (n = 594).
Study Case definition
criteria
Control subjects Patients with ME/CFS
n Observed Predicted % Predicted n Observed Predicted % Predicted
HEART RATE AT PEAK EXERTION
Bazelmans et al. (37) Fukuda 20 173 186 93.0 20 165 187 88.2
Blazquez et al. (38) Fukuda — — — — 32 129 180 71.7
Castro-Marrero et al.
(39)
Fukuda — — — — 73 140 171 81.9
Cook et al. (40) Fukuda 20 183 187 97.9 19 174 186 93.6
Cook et al. (41) Fukuda 19 163 177 92.1 15 156 178 87.6
Cook et al. (42) Fukuda 32 173 183 94.5 29 169 180 94.0
De Becker et al. (29) Fukuda 204 171 184 92.9 427 151 183 82.5
Fulcher and White (43) Oxford 30 182 183 99.5 66 171 183 93.4
Gallagher et al. (44) Oxford 42 183 185 98.9 41 178 182 97.8
Gibson et al. (45) Oxford 12 190 188 101.1 12 163 187 87.2
Hodges et al. (46) Fukuda, CCC, ICC 10 161 181 89.0 10 154 183 84.2
Ickmans et al. (47) Fukuda 13 165 191 86.4 30 145 184 78.8
Inbar et al. (48) Fukuda 15 172 177 97.2 15 150 177 84.8
Keller et al. (28) Fukuda — — — — 22 159 176 90.3
Kent-Braun et al. (49) Holmes — — — — 6 — — 93.0
Montague et al., (50) Holmes 41 152 184 82.6 41 124 184 67.4
Mullis et al. (51) Oxford — — — — 130 140 181 77.4
Nagelkirk et al. (52) Fukuda 19 163 177 92.1 15 156 178 87.6
Nijs et al. (53) Fukuda — — — — 64 140 180 77.8
Nijs et al. (54) Fukuda — — — — 240 144 186 77.4
Nijs et al. (55) Fukuda — — — — 77 140 179 78.2
Nijs et al. (56) Fukuda — — — — 28 146 178 82.0
Nijs et al. (57) Fukuda — — — — 16 159 182 87.4
Nijs et al. (58) Fukuda — — — — 156 152 181 84.0
Nijs et al. (59) Fukuda — — — — 36 146 181 80.7
Pardaens et al. (60) Fukuda — — — — 116 142 181 78.5
Riley et al. (61) Holmes 13 182 186 97.9 13 177 186 95.2
Robinson et al. (62) Fukuda 6 173 176 98.3 6 177 175 101.1
Sargent et al. (30) Fukuda 33 186 185 100.5 33 184 186 98.9
Shukla et al. (63) Fukuda 10 179 173 103.5 10 159 171 93.0
Sisto et al. (64) Holmes 22 178 187 95.2 21 161 186 86.6
Van Ness et al. (27) Holmes — — — — 179 140 177 79.1
Vermeulen et al. (65) Fukuda 15 167 184 90.7 15 158 184 86.4
Vermeulen and
Vermeulen van Eck (66)
Fukuda 18 159 175 90.8 223 158 182 85.9
Sample weighted mean — 172.3 183.4 94.0 — 149.8 181.4 82.2
95% confidence interval — 171.3–173.3 182.9–183.8 93.6-94.4 — 149.2–150.4 181.3–181.6 81.9–82.5
n, sample size; ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome; CCC, Canadian Consensus Criteria; ICC, International Consensus Criteria.
withME/CFS on two CPETs spaced 24 h apart. Two of the studies
(28, 65) used the Fukuda et al. criteria (4) and one study (46)
used a combination of the Fukuda et al. criteria (4), Canadian
Consensus Criteria (2), and International Consensus Criteria
(3). Raw HR data were extracted from each study at maximal
exertion and VAT, as available. Age-predicted maximum HR
values were calculated as 220 − mean agesample. Predicted VAT
HR values were taken as 70% of predicted maximumHR (71, 72).
Percentage of age-predicted maximum heart rate was computed
by dividing the observed exercise heart rate by its respective
age-predicted value.
Data from each study were pooled by calculating sample-
weighted mean values for HR and 95% confidence interval
(ConI) from the relevant studies, in order to conduct the
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TABLE 2 | Heart rate measurements obtained at ventilatory anaerobic threshold during a single maximal cardiopulmonary exercise test in studies comparing subjects
with myalgic encephalomyelitis/chronic fatigue syndrome (n = 795) to matched control subjects (n = 353).
Study Case definition
criteria
Control subjects Patients with ME/CFS
n Observed Predicted % Predicted n Observed Predicted % Predicted
HEART RATE AT VENTILATORY ANAEROBIC THRESHOLD
Cook et al. (42) Fukuda 32 112 128 87.4 29 109 126 86.5
De Becker et al. (29) Fukuda 204 150 129 116.5 427 135 128 105.4
Hodges et al. (46) Fukuda, CCC, ICC 10 137 127 108.1 10 134 128 104.6
Keller et al. (28) Fukuda — — — — 22 114 123 92.5
Nagelkirk et al. (52) Fukuda 19 110 124 88.7 15 111 125 88.8
Sargent et al. (30) Fukuda 33 126 130 97.2 33 127 130 97.5
Sisto et al. (64) Holmes 22 130 131 99.3 21 119 130 91.4
Vermeulen et al. (65) Fukuda 15 111 129 97.7 15 110 129 85.6
Vermeulen and
Vermeulen van Eck (66)
Fukuda 18 109 111 84.0 223 112 128 82.9
Sample weighted mean — 136.8 116.1 107.0 — 125.2 127.9 97.9
95% confidence interval — 135.1–138.4 115.4–116.8 105.9–108.1 — 124.5-125.9 127.7-128.0 97.4-98.4
n, sample size; ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome; CCC, Canadian Consensus Criteria; ICC, International Consensus Criteria.
TABLE 3 | Heart rate measurements obtained at peak exertion and ventilatory anaerobic threshold during a single maximal cardiopulmonary exercise test in studies
comparing females (n = 1,104) and males (n = 58) with myalgic encephalomyelitis/chronic fatigue syndrome.
Study Case definition
criteria
Females with ME/CFS Males with ME/CFS
n Observed Predicted % Predicted n Observed Predicted % Predicted
HEART RATE AT PEAK EXERTION
Blazquez et al. (38) Fukuda 32 126 187 71.7 — — — —
Castro-Marrero et al.
(39)
Fukuda 73 140 171 81.8 — — — —
Cook et al. (40) Fukuda 19 174 186 93.6 — — — —
De Becker et al. (29) Fukuda 427 151 183 82.5 — — — —
Ickmans et al. (47) Fukuda 30 145 184 78.8 — — — —
Montague et al. (50) Unknown 20 126 187 67.4 11 119 180 66.1
Nijs et al. (58) Fukuda 156 152 181 84.0 — — — —
Nijs et al. (59) Fukuda 36 146 181 80.7 — — — —
Pardaens et al. (60) Fukuda 116 142 181 78.5 — — — —
Robinson et al. (62) Fukuda — — — — 6 173 176 98.3
Sargent et al. (30) Fukuda 17 183 186 98.4 16 184 186 98.9
Vermeulen and
Vermeulen van Eck (66)
(CFS Only)
Fukuda 178 158 177 89.3 25 155 178 87.0
Sample weighted mean — 150.1 180.8 83.0 — 158.0 180.4 87.5
95% confidence interval — 149.0–151.1 180.4–181.2 82.6–83.4 — 152.8–163.3 178.9–181.8 85.4–89.7
HEART RATE AT VENTILATORY ANAEROBIC THRESHOLD
Sargent et al. (30) Fukuda 17 131 130 100.6 16 122 130 93.7
Vermeulen and
Vermeulen van Eck (66)
(CFS Only)
Fukuda 178 112 128 87.4 25 104 125 83.5
Sample weighted mean — 113.7 128.3 88.6 — 110.0 126.8 87.5
95% confidence interval — 111.8–115.5 128.1–128.5 87.3–89.9 — 107.1–114.9 125.6–128.0 85.2–89.7
N, sample size; ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome.
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following assessments: (1) to compare chronotropic responses
to exercise in individuals with ME/CFS compared to matched
control subjects, (2) to evaluate the effect of gender on HR
responses to activity in individuals with ME/CFS, (3) to
determine the effect of serial CPET on chronotropic response
in individuals with ME/CFS, and (4) to estimate the effect
of cardiovascular impairment on chronotropic response in
individuals with ME/CFS. In addition, standardized mean
difference and 95% ConI were calculated from studies that
compared ME/CFS to matched control subjects, in order to
estimate the magnitude of effect (73). A variance weighted
summary also was calculated to pool the results across all studies.
These results were used to generate forest plots for the data
at peak exertion (Figure 2) and ventilatory anaerobic threshold
(Figure 3). Q and I2 statistics were assessed to determine
the amount of statistical heterogeneity across studies (74).
Pooled standard deviations were computed using a random
effects model. Point estimates for pooled data were compared
using independent samples t-tests. All analyses were considered
statistically significant at p < 0.05.
Comparisons Between Patients With
ME/CFS and Matched Control Subjects
There were 36 studies that reported heart rate responses at
peak exertion in individuals with ME/CFS (n = 2,270) and 21
studies involving matched control subjects (n = 594; Table 1).
Control subjects performed at 94.0% of age-predicted maximum
HR (95%ConI: 93.6–94.4%), while individuals with ME/CFS
performed at 82.2% (81.9–82.5%) of age-predicted maximum
HR (p < 0.0001). Almost all the studies measured a decreased
peak HR in individuals with ME/CFS. The standardized mean
difference (d) for these data was −1.37 (95%ConI: −1.46
to −1.26), which indicates a very large effect, and 92% of
the ME/CFS group had a peak exercise heart rate that was
below the matched control group. This corresponded to an
unstandardized mean difference of 11.2 fewer beats per minutes
in patients with ME/CFS compared to matched control subjects
(95%ConI: 6.9–15.4 bpm decrease). Significant heterogeneity
was present in available studies (Q = 113.8, p < 0.0001;
I2: 82%), so these pooled difference estimates should be
viewed with caution. Despite the heterogeneity present in
this literature for each pooled effect size estimate, the high
number of included studies and pooled sample size provides
for substantial statistical power. Potential sources of variability
in the published literature include the differences in case
definitions used for ME/CFS, fitness levels of matched control
subjects relative to patients with ME/CFS, testing modality
(i.e., treadmill vs. bicycle), and statistical noise introduced
by reliability of criteria to select peak performance between
studies. Despite these methodological differences, published data
indicate the presence of statistically significant and clinically
relevant impairment in chronotropic response to exercise at
peak exertion in individuals with ME/CFS compared to matched
control subjects.
Twelve datasets from nine studies documented chronotropic
responses at VAT in individuals with ME/CFS (n = 795)
FIGURE 2 | Standardized mean differences (d) for heart rate at peak exertion
during maximal cardiopulmonary exercise testing, comparing patients with
ME/CFS (n = 1,053) and matched control subjects (n = 569). Boxes represent
point estimates, and whiskers are 95% confidence intervals. Patients with
ME/CFS had lower peak heart rates than matched control subjects (large
effect size).
compared to control subjects (n= 353; Table 2). Overall, control
subjects performed at 107.0% (95%ConI: 105.9–108.1%) and
individuals with ME/CFS performed at 97.9% (95%ConI: 97.4–
98.4%) of their age-predicted heart rates (p < 0.0001). This
finding indicates patients with ME/CFS, on average, remained
relatively impaired when compared to age- and sex-matched
control subjects. Seven of nine studies documenting chronotropic
responses at VAT showed a decrease in patients with ME/CFS
compared to matched control subjects, while the remaining two
studies found slight increases. Overall, the standardized mean
difference (d) for these data was −0.53 (95%ConI: −0.65 to
−0.40), which indicates a moderate effect. Sixty-three percent
of patients with ME/CFS had lower heart rates at VAT than
matched controls in the context of a single test. These findings
correspond to an unstandardized mean difference of 5.4 fewer
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FIGURE 3 | Standardized mean differences (d) for exercise heart rate at
ventilatory anaerobic threshold (VAT), comparing patients with ME/CFS
(n = 778) and matched control subjects (n = 378). Boxes represent point
estimates, and whiskers are 95% confidence intervals. Patients with ME/CFS
had lower heart rates at VAT than matched control subjects (moderate
effect size).
beats per minutes in patients withME/CFS compared to matched
control subjects (95%ConI: 1.5–9.2 bpm decrease). Moderate
heterogeneity was present in available studies (Q = 30.01,
p < 0.01; I2 = 60%). Like the peak exercise analysis, the relatively
high pooled sample size provides substantial statistical power.
However, it is notable that data evaluating heart rate at VAT
from De Becker et al. (29) and Vermeulen and Vermeulen
van Eck (66) differ by over 20 percentage points in people
with ME/CFS (105.1 and 85.6%, respectively), and exert a large
influence on sample-weighted means for observed heart rate
and percent of predicted heart rate due to large sample sizes
(n = 427 and n = 204, respectively). This observation highlights
the need to consider the unique physiological characteristics
of individual patients with ME/CFS. Some of the observed
variation also may be attributed to heterogeneous methods
used to select VAT used in the literature, indicating the
need to identify and observe uniform methods of CPET
analysis (75).
Comparisons Between Females and Males
With ME/CFS
Articles describing two studies of CPET measurements in
individuals with ME/CFS permitted abstraction of data by
subject sex (30, 66), involving 1,104 females and 58 males with
measurements at peak exertion and 41 males and 195 females
with measurements at VAT (Table 3). Males demonstrated a
significantly higher achievement of age-predicted maximum
heart rate at peak exertion (females: 83.0%, 95%ConI: 82.6–
83.4%; males: 87.5%, 95%ConI: 85.4–89.7%; p < 0.0001) but
not VAT (females: 88.6%, 95%ConI: 87.3–89.9%; males: 87.5%,
95%ConI: 85.2–89.7%; p = 0.476). These data suggest that,
although there may be important sex-related features in ME/CFS
incidence, the expression of CI inME/CFS appears homogeneous
between sexes at submaximal workloads (75). Additional studies
of sex-related difference in CI at peak levels of exertion are
warranted, because male patients with ME/CFS appear under-
represented in the literature to date.
Comparisons Between Measurements
Obtained During Serial CPETs
There were three studies involving two CPETs conducted 24 h
apart (28, 46, 65), comprising 47 patients with ME/CFS and 35
matched control subjects (Table 4). On the first CPET at maximal
exertion, individuals with ME/CFS demonstrated a significantly
lower heart rate response that was 87.9% of predicted by age
(95%CI: 86.9–88.9%) compared to control subjects with a heart
rate response of 90.0% of predicted by age (95%ConI: 89.5–
90.5%; p < 0.01). On the second CPET at peak exertion, control
subjects maintain the heart rate response to exercise compared
to age-predicted norms (90.6%; 95%ConI: 90.1–91.1%) but
individuals with ME/CFS demonstrated a significant decline
compared to control subjects (84.3%; 95%ConI: 83.9–84.7%;
p < 0.05). Although peak exertion is not common in daily life,
sympathetic autonomic drive is maximal during peak exertion,
so this observed difference may magnify subtle decrements in
sympathetic autonomic drive that may only inconsistently be
observed during lower levels of physical exertion.
During the first CPET at VAT, individuals with ME/CFS
achieved 92.4% of predicted heart rate (95%ConI: 89.6–95.2)
and control subjects achieved 95.0% of predicted heart rate
(95%ConI: 88.9–101.0), which was not significantly different
(p = 0.387). However, during the second CPET at VAT,
individuals with ME/CFS decreased slightly (90.6%, 95%ConI:
88.1–93.6%) while matched control subjects increased (101.1%,
95%ConI: 94.5–107.6%), resulting in a significant difference
in percentage of predicted HR achieved between groups on
the second CPET (p < 0.01). The observed reduction of
10 beats per minute in patients with ME/CFS compared
to matched control subjects in the post-exertional state also
appears to be clinically important, because it represents a
decrement in repeated submaximal functioning that is consistent
with the relatively narrow physiological range for many usual
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TABLE 4 | Heart rate measurements obtained at peak exertion and ventilatory anaerobic threshold during studies involving two cardiopulmonary exercise tests in
individuals with myalgic encephalomyelitis/chronic fatigue syndrome (n = 47) and matched control subjects (n = 35).
Study Case definition
criteria
Test 1 Test 2
n Observed Predicted % Predicted n Observed Predicted % Predicted
HEART RATE AT PEAK EXERTION IN PATIENTS WITH ME/CFS
Hodges et al. (46) Fukuda, CCC, ICC 10 154 183 84.2 10 151 183 82.5
Keller et al. (28) Fukuda 22 160 176 90.9 22 150 176 85.2
Vermeulen et al. (65) Fukuda 15 158 184 85.7 15 155 184 84.2
Sample weighted mean — 158.1 180.0 87.9 — 151.8 180.0 84.3
95% confidence interval — 157.2–159.0 178.8–181.3 86.9–88.9 — 151.1–152.6 178.8–181.3 83.9–84.7
MEASUREMENTS AT PEAK EXERTION IN CONTROL SUBJECTS
Hodges et al. (46) Fukuda, CCC, ICC 10 161 181 89.0 10 162 181 89.5
Vermeulen et al. (65) Fukuda 15 167 184 90.8 15 168 184 91.3
Sample weighted mean — 164.6 182.8 90.0 — 165.6 182.8 90.6
95% confidence interval — 162.9–166.3 182.0–183.6 89.5–90.5 — 163.9–167.6 182.0–183.6 88.1–93.6
HEART RATE AT VENTILATORY ANAEROBIC THRESHOLD IN PATIENTS WITH ME/CFS
Hodges et al. (46) Fukuda, CCC, ICC 10 134 128 104.6 10 133 128 103.8
Keller et al. (28) Fukuda 22 113 123 91.7 22 108 123 87.7
Vermeulen et al. (65) Fukuda 15 110 129 85.4 15 112 129 87.0
Sample weighted mean — 116.5 126.0 92.4 — 114.5 126.0 90.9
95% confidence interval — 112.8–120.2 125.2–126.9 89.6–95.2 — 110.8–118.4 125.2–126.9 88.1–93.6
MEASUREMENTS AT VENTILATORY ANAEROBIC THRESHOLD IN CONTROL SUBJECTS
Hodges et al. (46) Fukuda, CCC, ICC 10 137 127 108.1 10 146 127 108.3
Vermeulen et al. (65) Fukuda 15 111 129 86.2 15 118 129 91.6
Sample weighted mean — 121.4 128.0 95.0 — 129.2 128.0 101.0
95% confidence interval — 95.9–146.9 127.4–128.5 88.9–101.0 — 121.4–137.0 127.4–128.5 95.4–107.6
n, sample size; ME/CFS, myalgic encephalomyelitis/chronic fatigue syndrome; CCC, Canadian Consensus Criteria; ICC, International Consensus Criteria.
daily activities. The relatively small pooled sample sizes for
this analysis suggest the need for future studies to examine
test-retest effects in chronotropic and other responses to
exercise, in the context of measurements obtained during
standardized maximal CPET methodologies. The heterogeneity
of findings at VAT on serial CPET also highlights the need
to adhere to strict patient selection standards and a uniform
methodology for conducting CPET and selecting VAT across
future studies (75).
Comparisons Between Levels of Severity
in ME/CFS
One article contained data 179 individuals with ME/CFS
that allowed for analysis of chronotropic response based on
cardiovascular impairment (Table 6) (27). In this study, subjects
were classified according to the American Medical Association
Guidelines for the Evaluation of Permanent Impairment (AMA)
impairment level based on peak volume of oxygen consumed
(VO2). Classifications included no impairment (n = 20), mild
impairment (n= 67), moderate impairment (n= 72), and severe
impairment (n = 20). At maximal exertion, individuals with
no impairment achieved 91.1% of age-predicted maximum HR.
There was a general trend toward a declining percentage of
age-predicted maximum HR with increasing AMA impairment
level. Individuals with ME/CFS and mild AMA impairment
reached 83.1% of age-predicted maximum HR, whereas those
with moderate AMA impairment demonstrated 75.1% of age-
predicted maximum HR, and individuals with severe AMA
impairment only achieved 67.6% of age-predicted maximumHR.
These data suggest the potential presence of a clinically important
interaction between cardiovascular impairment and CI, in which
functional impairment categories could be related to increasing
levels of autonomic impairment.
RELEVANCE OF CI TO
PATHO-ETIOLOGICAL STUDIES
IN ME/CFS
Chronotropic responses during exercise result from a balance
of neural and humoral influences on the intrinsic firing
rate of sinoatrial (SA) and atrioventricular (AV) node cells
(Figure 4). The normal discharge rate of sinoatrial node cells
provides 100 beats per minute (76). In the resting state
influence from parasympathetic fibers from the vagus nerve
depresses heart rate to the normal range of 60–100 beats per
minute. Parasympathetic effects on the SA and AV nodes are
mediated through cholinergic inputs (76). Acetylcholine binds
to muscarinic receptors on the cardiac muscle, SA node, and
AV node (76). Sympatho-adrenal-medullary responses mediate
the increase in heart rate commensurate with exercise workload.
Sympathetic fibers innervate the myocardium, conduction
system, SA node, and AV node, which act on cardiac structures
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FIGURE 4 | Heart rate responses to exercise in non-ME/CFS (solid line) and ME/CFS (dashed line). Arrow sizes represent the direction and magnitude of the
influence of the dominant controllers of heart rate in shaded region.
through the release of epinephrine at the neuromuscular
junction (76) In addition, cardiac structures are responsive
to circulating catecholamines from blood (epinephrine) (76).
ß1-adrenoreceptors and ß2-adrenoreceptors are located on the
myocardium, conduction system, SA node, and AV node, which
bind epinephrine and norepinephrine (76). The net effect of
adrenergic inputs is to increase heart rate above 100 beats
per minute, such as during periods of distress or exercise.
Following adrenergic/cholinergic binding on cardiac structures,
local signal transduction is responsible for observed changes in
heart rate (76).
The balance of cardiac neural control necessary for normal
exercise-related changes in heart rate implicates the potential
importance of impaired cardiac neural control to explain
impairments in exercise-related heart rate change (77).
Specifically, blunted changes in exercise-related heart rate
could be linked to four major abnormalities of cardiac neural
regulation. Down-regulation of ß1 and/or ß2 adrenoreceptors
might result in adrenergic insensitivity, and limited rise in heart
rate during exercise. Second, sympathetic fiber dysfunction
could result in decreased norepinephrine output, which would
reduce the adrenergic effects on cardiac structures and reduce
exercise-related changes in heart rate. Third, diminished
sympatho-adrenal-medullary activation may result in smaller
rises in epinephrine. Finally, a relative dominance of vagus
(cholinergic) inputs inhibit the influence of epinephrine and
norepinephrine on local cardiac structures, and therefore
blunt heart rate increases with increasing exercise workloads.
This “cholinergic dominance” hypothesis would appear to be
in line with existing conceptual work by Van Elzakkar (78).
However, the specific mechanisms that cause or predispose to CI
largely remain unclear. Intolerance of sympathetic autonomic
endocrine signaling, myocardium, SA node, AV node, and
TABLE 5 | Raw and percent differences in metabolic equivalents between
individuals with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
and matched sedentary individuals during serial cardiopulmonary exercise testing














% Difference, Peak −16.3%








% Difference, Peak −8.2%
CPET2








% Difference, Peak −14.7%








% Difference, VAT −19.4%
Decremented performance was noted in individuals with ME/CFS on the second CPET at
peak exertion and ventilatory anaerobic threshold, indicating the physiological correlates of
post-exertional malaise. Measurements are expressed as mean (standard deviation) and
95% confidence interval. CPET, cardiopulmonary exercise test; HR, heart rate; ME/CFS,
myalgic encephalomyelitis/chronic fatigue syndrome; METs, metabolic equivalents; VAT,
ventilatory anaerobic threshold.
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TABLE 6 | Chronotropic response to exercise measured during a single maximal
cardiopulmonary exercise test in individuals with myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS), based on re-analysis of









PEAK EXERTION (MEASURED HEART RATE)
Predicted HR 179 177 177 173
Actual HR 163 147 133 117
% Predicted 91.1 83.1 75.1 67.6
70% EXERTION (CALCULATED HEART RATE)
Predicted HR 126 124 124 121
Actual HR 114 102 93 82
% Predicted 90.4 82.3 75.0 67.8
(The authors used the Holmes criteria to identify ME/CFS). At both peak exertion and
ventilatory anaerobic threshold, the difference between age-predicted heart rate and
observed heart rate increased as American Medical Association metabolic impairment
category worsened. HR, heart rate.
conduction system all have been implicated in CI in various
pathophysiological conditions (22, 79), and also have been
suggested as a cause of PEM in ME/CFS (80, 81).
RELEVANCE OF CI TO EXERCISE TESTING
AND ANALEPTIC MANAGEMENT
FOR ME/CFS
One approach to circumvent potential challenges associated
with maximal exercise testing is the use of submaximal exercise
testing. Submaximal exercise paradigms have been proposed as
a safer alternative to maximal cardiopulmonary exercise testing
(82), because it is thought to be less likely to create severe,
long-lasting symptoms in people with ME/CFS. One example
of a submaximal test paradigm involves a sustained 25-min
bout of work at 70% of age-predicted maximum heart rate
(83). This type of “submaximal” physiological stressor has been
used in a number of studies involving patients with ME/CFS.
However, the presence of abnormal heart rate responses to
exercise in people with ME/CFS suggests a potential to over-
estimate workload based on predicted heart rate, which in turn,
risks having subjects exert harder than intended during tests that
are putatively “submaximal.”
Although participants with ME/CFS in studies that use
submaximal exercise test paradigms generally demonstrate
averaged exercise heart rates that are statistically similar to
control subjects, it seems notable that participants achieve
statistical similarity at significantly lower averaged workloads and
averaged VO2 (83). Because cardiac, pulmonary, and metabolic
measurements using submaximal protocols are not performed
to peak exertion, it is impossible to determine the AMA
impairment category or evaluate VAT for each subject, which
prevents the estimation of potential effects of CI on actual
exertion levels for patients with ME/CFS. In addition, it is
possible that at least some patients with ME/CFS in studies using
submaximal exercise paradigms could have been performing
TABLE 7 | Oxygen needs (expressed in METs) required to complete common
activities of daily living (85), and assessment whether they occur under ventilatory
anaerobic threshold (VAT) in individuals with myalgic encephalomyelitis/chronic






Pre PEM Post PEM
Circuit training 4.3 No No No
Driving automobiles 2.5 Yes Yes Yes
Folding laundry 2.3 Yes Yes Yes
Food preparation 3.5 No No Yes
Food shopping 2.5 Yes Yes Yes
Light bicycling 3.5 No No Yes
Light calisthenics 3.5 No No Yes
Lying quietly 1.0 Yes Yes Yes
Making the bed 3.5 No No Yes
Mild stretching 2.3 Yes Yes Yes
Moderate bicycling 6.8 No No Yes
Moderate cleaning 3.5 No No Yes
Playing with children 3.5 No No Yes
Scrubbing floors 3.5 No No Yes
Showering 2.0 Yes Yes Yes
Sitting quietly 1.3 Yes Yes Yes
Sleeping 0.95 Yes Yes Yes
Standing quietly 1.3 Yes Yes Yes
Sweeping 3.3 Yes No Yes
Vacuuming 3.3 Yes No Yes
Vigorous bicycling 8.8 No No No
Walking <2.0 mph 2.0 Yes Yes Yes
Walking 3.0 mph 3.5 No No Yes
Walking 3.5 mph 4.3 No No No
Washing dishes 2.5 Yes Yes Yes
Washing windows 3.5 No No Yes
Watering plants 2.5 Yes Yes Yes
Activities falling under the 95% confidence interval for VAT from data reported by Snell
et al. (26) were considered under VAT. Likely differences in activity tolerance between
individuals with ME/CFS and sedentary individuals appear in bold. ME/CFS, myalgic
encephalomyelitis/chronic fatigue syndrome; METs, metabolic equivalents; PEM, post-
exertional malaise; VAT, ventilatory anaerobic threshold.
maximal tests. For example, Cook et al. (83) published data
on RER values for patients with ME/CFS and controls. The
reported 99% confidence interval for averaged respiratory
exchange ratio was 1.1 for people with ME/CFS but not control
subjects. This observation suggests the potential for maximal
exertion in some participants with ME/CFS but not control
subjects (83), because RER values >1.15 are one criterion to
determine a maximal CPET (84). These data point to important
cautions about extrapolating the idea of submaximal tests
to people with ME/CFS without individualized measurement
and analysis.
Consideration of CI during submaximal exercise is critical
to understanding the results of exercise studies using these
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putatively submaximal methodologies. The presence of CI
suggests that it is difficult to determine whether each participant
with ME/CFS receives a standardized dose of the physiologic
stressor; indeed, the previously observed trend of CI makes
it possible that the participants with ME/CFS who have more
impairment may have received a proportionally greater stressor
than participants with less impairment. For example, individuals
classified as having no AMA impairment might be exerting sub-
maximally at approximately 70% of age-predicted heart rate but
individuals with moderate to severe AMA impairment actually
might perform supra-maximally (33). Given the relatively
low number of participants with ME/CFS in studies using
submaximal exercise methodologies, careful standardization of
the exercise stressor appears important to ensure that measures
of blood chemistry, imaging and cognitive-perceptual data do not
have outliers. Uniformity in sample characteristics and exercise
stressor is made more important by the fact that neither sample
size calculations nor tests of data normality are commonly
reported in studies using submaximal methodologies.
Volume of oxygen consumed (VO2) depends on a robust
chronotropic response because heart rate rise during exercise
increases cardiac output, and therefore the amount of oxygen
available to tissues. Thus, CI may explain low achieved VO2 at
peak and VAT, especially when observed on a second CPET (26).
These data suggest an interaction effect between group and test
at VAT, in which there is a greater reduction in VO2 at VAT in
people with ME/CFS than matched, sedentary control subjects
(26). Wemeasured a 19.4% difference in VO2 at VAT on a second
CPET, which we believe reflects a clinically significant reduction
in capacity for normal daily activities or ADLs (Table 5).
Many ADLs are conducted above VAT in people withME/CFS
(Table 7), which may predispose them to the development of
PEM. A single bout of exercise may lower the VO2 observed
on a second test, which causes even more ADLs to exceed
VO2 at VAT in the post-exertional state. This observation
is relevant because energy expenditures at, or close to VAT,
represent vigorous activity and can be sustained for only short
periods of time (Table 7). The International Labor Organization
regard 30% or less of maximal VO2 as the threshold for
acceptable physiological demands over an 8-h work day. For
a 12-h work day this is reduced to 23% or less and limited
to physically light work. Extended working hours are not
advisable when job-related mental or emotional stresses are high.
Estimated energy expenditures for most occupations and life
activities can be found in the online Compendium of Physical
Activities (85).
CONCLUSION
This literature synthesis supports the presence of abnormally
blunted HR responses to activity in people with ME/CFS, at
bothmaximal exertion and submaximal VAT. Pathophysiological
processes consistent with autonomic dysregulation should be
prioritized for etiologic studies in ME/CFS, independent of
distal pathogenic causes and proximal multi-system effects.
The abnormal heart rate response to exercise in people with
ME/CFS indicates that exercise testing based on a percentage
of maximal heart rate cannot be considered “submaximal”
in people with ME/CFS and presents a clear risk for
supramaximal exertion during “submaximal” exercise tasks in
the most severely involved individuals. Pacing self-management
plans based on age-predicted heart rate thresholds should be
viewed with caution, because the chronotropic response is
impaired in people with ME/CFS. Threshold heart rates for
effective analeptic management and the etiology of observed
CI in people with ME/CFS should be formally established
through adequately powered studies that involve serial maximal
CPET methodologies.
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